The company said its board appointed J. David Joyner as president and chief executive officer effective October 17, 2024, and that Karen S. Lynch stepped down from both roles and from the board on the same day. Roger N. Farah was named executive chairman.

1. 01

   The company said its board appointed J. David Joyner as president and chief executive officer effective October 17, 2024, and that Karen S. Lynch stepped down from both roles and from the board on the same day. Roger N. Farah was named executive chairman.

2. 02

   The company gave preliminary guidance for Q3 2024 GAAP diluted earnings per share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. It said these figures are current estimates and may change once closing and review procedures are complete.

3. 03

   The company said it recorded premium deficiency reserves of about $1.1 billion in Q3, related to its Medicare and Individual Exchange businesses, which lowered Adjusted EPS by $0.63. GAAP results also include restructuring costs of about $1.2 billion tied to incremental store closures in 2025.

4. 04

   The company said its Medical Benefit Ratio (MBR) for Q3 is expected to be about 95.2%, including a 220-basis point impact from premium deficiency reserves. It also said that medical cost trends exceeded its prior outlook, and it advised investors to stop relying on the guidance it gave on August 7, 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.